APA (7th ed.) Citation

Goswami, J., Cardona, J. F., Caso, J., Hsu, D. C., Simorellis, A. K., Wilson, L., . . . Das, R. (2025, September 23). Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years. Clinical infectious diseases. https://doi.org/10.1093/cid/ciaf515

Chicago Style (17th ed.) Citation

Goswami, Jaya, et al. "Safety, Tolerability, and Immunogenicity of Revaccination with MRNA-1345, an MRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years." Clinical Infectious Diseases 23 Sep. 2025. https://doi.org/10.1093/cid/ciaf515.

MLA (9th ed.) Citation

Goswami, Jaya, et al. "Safety, Tolerability, and Immunogenicity of Revaccination with MRNA-1345, an MRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years." Clinical Infectious Diseases, 23 Sep. 2025, https://doi.org/10.1093/cid/ciaf515.